Aldevron, a global leader in the manufacture of plasmid DNA, mRNA and proteins, has promoted Venkata Indurthi to Vice President of Research and Development (R&D). He will begin this new role immediately and continue reporting to John Ballantyne, Co-founder and Chief Scientific Officer while having direct access to Aldevron’s senior executive team.
Aldevron, a leading manufacturer of plasmid DNA, proteins and mRNA, today announced the sale of its Germany based antibody discovery business. Brian Walters, current president of the business unit and longtime employee of Aldevron, led a group of investors to purchase the business for an undisclosed amount. The transaction is effective immediately.
Aldevron The First To Rapidly Discover Human Antibodies Using Ligands Omnirat® Platform And Berkeley Lights Beacon® Instrument
Aldevron, a leading provider of antibody discovery and production services, today announced the successful discovery of human antibodies utilizing the combination of three powerful platforms, Aldevron’s GENOVAC® genetic immunization and cell-based screening, Ligand’s OmniRat® therapeutic antibody platform and Berkeley Lights’ Beacon® platform.
Aldevron LLC, a company angling for a role in the production of Covid-19 vaccines, hired Rachel Lei as its first general counsel and corporate secretary.
Lei became Aldevron’s first general counsel in June. She joins new chief executive officer Kevin Ballinger, hired the following month, among other recent additions to the North Dakota-based company’s leadership team.
Rachel Lei has joined Aldevron as its new General Counsel and Corporate Secretary. Lei will advise the Board of Directors and CEO on issues of overarching importance to Aldevron and will assist in setting and implementing Aldevron’s overall strategic direction , building and overseeing Aldevron’s legal department to ensure that its legal function operates as a true business partner.
In the news: GEN Magazine - Plasmid Manufacturer Scales Up Production Capacity to Serve New Therapeutics
A plasmid DNA manufacturer is planning to scale up its production capacity to meet the growing needs of gene therapy. Aldevron, a company based in North Dakota, expects to open a new 189,000 sq. ft facility in spring 2021 to add to their existing 70,000 sq. ft of manufacturing space.
Aldevron, the leading plasmid DNA, proteins and mRNA manufacturing company, is pleased to announce the hiring of Kenneth (Ken) Bonnell as Vice President of Quality and Regulatory Affairs.
Aldevron, the leading plasmid DNA manufacturing company, has expanded its leadership team by appointing Cynthia Biffert as Vice President of its GMP Nucleic Acids Business Unit (NABU).
Ziopharm Oncology, Inc. (NASDAQ: ZIOP), is collaborating with Aldevron to secure rapid neoGMP® plasmid DNA manufacturing for Ziopharm's Sleeping Beauty construct to express TCRs for treatment of solid tumors.